Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mohler

Showing results (321-330 of 368) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2012
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cellsShahriar Koochekpour, Sunipa Majumdar, Gissou Azabdaftari, et al.
The Prostate|February 24, 2022
Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up studyMadhav K C, Evrim Oral, Ariane L Rung, et al.
The Prostate|July 13, 2022
Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patientsRenjie Jin, Connor Forbes, Nicole L Miller, et al.
The Prostate|January 3, 2013
The association between calcium channel blocker use and prostate cancer outcomeMichael A Poch, Diana Mehedint, Dawn J Green, et al.
The Prostate|March 14, 2020
A CD24-p53 axis contributes to African American prostate cancer disparitiesWei Liu, Yue Zhang, Shi Wei, et al.
Journal of the National Cancer Institute|October 10, 2014
The Thoc1 ribonucleoprotein and prostate cancer progressionMeenalakshmi Chinnam, Yanqing Wang, Xiaojing Zhang, et al.
Molecular Endocrinology (Baltimore, Md.)|March 30, 2012
RhoA as a mediator of clinically relevant androgen action in prostate cancer cellsLucy J Schmidt, Kelly Duncan, Neelu Yadav, et al.
European Urology|July 25, 2016
Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic PrognosticatorsLei Wei, Jianmin Wang, Erika Lampert, et al.
Plos One|January 4, 2014
Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammationRamesh Narayanan, Muralimohan Yepuru, Christopher C Coss, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Impact of an NCCN-Compliant Multidisciplinary Conference on Treatment Decisions for Localized Prostate CancerAhmed A Hussein, Umar Iqbal, Zhe Jing, et al.
Pageof 37

Showing results (321-330 of 368) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2012
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cellsShahriar Koochekpour, Sunipa Majumdar, Gissou Azabdaftari, et al.
The Prostate|February 24, 2022
Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up studyMadhav K C, Evrim Oral, Ariane L Rung, et al.
The Prostate|July 13, 2022
Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patientsRenjie Jin, Connor Forbes, Nicole L Miller, et al.
The Prostate|January 3, 2013
The association between calcium channel blocker use and prostate cancer outcomeMichael A Poch, Diana Mehedint, Dawn J Green, et al.
The Prostate|March 14, 2020
A CD24-p53 axis contributes to African American prostate cancer disparitiesWei Liu, Yue Zhang, Shi Wei, et al.
Journal of the National Cancer Institute|October 10, 2014
The Thoc1 ribonucleoprotein and prostate cancer progressionMeenalakshmi Chinnam, Yanqing Wang, Xiaojing Zhang, et al.
Molecular Endocrinology (Baltimore, Md.)|March 30, 2012
RhoA as a mediator of clinically relevant androgen action in prostate cancer cellsLucy J Schmidt, Kelly Duncan, Neelu Yadav, et al.
European Urology|July 25, 2016
Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic PrognosticatorsLei Wei, Jianmin Wang, Erika Lampert, et al.
Plos One|January 4, 2014
Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammationRamesh Narayanan, Muralimohan Yepuru, Christopher C Coss, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Impact of an NCCN-Compliant Multidisciplinary Conference on Treatment Decisions for Localized Prostate CancerAhmed A Hussein, Umar Iqbal, Zhe Jing, et al.
Pageof 37